20682708

Source:http://linkedlifedata.com/resource/pubmed/id/20682708

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0205179, umls-concept:C0280100, umls-concept:C0920321, umls-concept:C1706888, umls-concept:C1999216
pubmed:issue	18
pubmed:dateCreated	2010-9-16
pubmed:abstractText	This phase I, open-label, dose-escalation study investigated the maximum tolerated dose (MTD) of BI 2536, a small-molecule polo-like kinase (Plk)-1 inhibitor, in two treatment schedules in patients with advanced solid tumors. Secondary objectives included evaluation of safety, efficacy, and pharmacokinetics.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9502500
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/BI 2536, http://linkedlifedata.com/resource/pubmed/chemical/Cell Cycle Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Protein-Serine-Threonine Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Pteridines, http://linkedlifedata.com/resource/pubmed/chemical/polo-like kinase 1
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	1078-0432
pubmed:author	pubmed-author:Al-BatranSalah-EddinSE, pubmed-author:FritschHolgerH, pubmed-author:HochhausAndreasA, pubmed-author:HofheinzRalf-DieterRD, pubmed-author:JägerElkeE, pubmed-author:MunzertGerdG, pubmed-author:ReichardtVolker LVL, pubmed-author:TrommeshauserDirkD
pubmed:copyrightInfo	©2010 AACR.
pubmed:issnType	Print
pubmed:day	15
pubmed:volume	16
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	4666-74
pubmed:dateRevised	2011-11-2
pubmed:meshHeading	pubmed-meshheading:20682708-Adult, pubmed-meshheading:20682708-Aged, pubmed-meshheading:20682708-Aged, 80 and over, pubmed-meshheading:20682708-Antineoplastic Agents, pubmed-meshheading:20682708-Cell Cycle Proteins, pubmed-meshheading:20682708-Disease Progression, pubmed-meshheading:20682708-Dose-Response Relationship, Drug, pubmed-meshheading:20682708-Drug Administration Schedule, pubmed-meshheading:20682708-Female, pubmed-meshheading:20682708-Humans, pubmed-meshheading:20682708-Male, pubmed-meshheading:20682708-Middle Aged, pubmed-meshheading:20682708-Neoplasms, pubmed-meshheading:20682708-Protein Kinase Inhibitors, pubmed-meshheading:20682708-Protein-Serine-Threonine Kinases, pubmed-meshheading:20682708-Proto-Oncogene Proteins, pubmed-meshheading:20682708-Pteridines, pubmed-meshheading:20682708-Treatment Outcome
pubmed:year	2010
pubmed:articleTitle	An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
pubmed:affiliation	Universitätsmedizin Mannheim, Heidelberg University, Mannheim, Germany.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I